康寧傑瑞製藥-B(09966.HK)獲納入深港通下的港股通股票名單
格隆匯 12 月 28日丨康寧傑瑞製藥-B(09966.HK)發佈公吿,根據深圳證券交易所於2020年12月25日發佈的《關於深港通下的港股通股票名單調整的公吿》,公司已獲納入深港通下的港股通股票名單,並於2020年12月28日生效。
董事會認為,公司獲納入深港通下的港股通股票名單表明資本市場的投資者對公司業務、股票流通性及未來前景的肯定,預期此將擴大公司股東基礎、多元化公司股東結構及增加股份流動性;並相信獲納入名單將促進實現公司的投資價值及提高公司在資本市場的聲譽。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.